Figure S3


A
HCC1954 (PIK3CA H1047R)
0min
15min
30min
1hr
2hr
4hr
6hr
8hr
DMSO
1 μM
5 μM
Taselisib
Membrane
p110α
Ras
Cytosol
Actin
HCC1954 (PIK3CA H1047R)
Alpelisib
B
HCC1954 (PIK3CA H1047R)
Taselisib
Alpelisib
8hr treatment
DMSO
0.02μM
0.06μM
0.18μM
0.53μM
1.6μM
p110α
pAKT S473
Actin
HDQ-P1 (PIK3CA WT)
110
C
PIK3CA expression after taselisib
Relative expression
PIK3CA WT
PIK3CA H1047R
PIK3CA expression after BYL719
D
Vehicle control
Taselisib 15mg/kg
Alpelisib 40mg/kg
4hr
RAS
Vehicle control
GDC-0077 50mg/kg
GDC-0077 50mg/kg
1hr
8hr

Figure S3

Taselisib and GDC-0077 induce mutant p110α and not WT p110a degradation

(A) Subcellular fractionation of HCC1954 PIK3CA H1047R mutant cells treated with PI3K inhibitors taselisib or BYL719 for up to 8 hours, followed by p110α western blot.

(B) Taselisib and BYL719 treatment for 8 hours in HCC1954 PIK3CA H1047R mutant cells and HDQ-P1 PIK3CA-wild-type cells.

(C) Quantitative RT-PCR shows no reduction in PIK3CA RNA expression in HCC1954 cells treated with taselisib or BYL719 for up to 24 hours. Error bars are standard deviation of triplicates.

(D) Membrane-associated p110a expression following single oral dose of 15 mg/kg taselisib, 40 mg/kg BYL719, or 50 mg/kg GDC-0077 treatment in HCC1954 xenograft tumors.